Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.21.2
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 78 Months Ended
Jun. 18, 2021
May 05, 2020
Oct. 21, 2019
May 31, 2016
Jan. 31, 2015
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Apr. 30, 2013
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           $ 442,408,000 $ 301,207,000 $ 987,573,000 $ 512,674,000    
Milestone revenue recognized               $ 7,425,000      
Nicoya                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Upfront payment from development and license agreement $ 5,000,000                    
Period after first commercial sale 10 years                    
Pfizer | Products                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Maximum milestone payments         $ 275,000,000.0            
Additional milestone payment         275,000,000.0            
Annual height velocity at point in time     12 months                
Non-refundable and non-creditable upfront payment         295,000,000.0            
Milestone revenue recognized                   $ 0  
Minimum | Pfizer | Products                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Each milestone payment         20,000,000.0            
Maximum | Pfizer | Products                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Each milestone payment         $ 90,000,000.0            
Pharmsynthez                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Ownership percentage, equity method           9.00%   9.00%   9.00% 9.00%
Phase Three Initiation | Nicoya                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Upfront payment from development and license agreement $ 5,000,000                    
Regulatory and Development | Nicoya                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Milestone payment from development and license agreement $ 115,000,000                    
Transfer of intellectual property and other                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           $ 9,548,000 20,880,000 $ 13,816,000 30,433,000    
Transfer of intellectual property and other | Products                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues   $ 3,000,000                  
Transfer of intellectual property and other | Nicoya | Products                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           5,000,000.0   5,000,000.0      
Transfer of intellectual property and other | Pfizer | Products                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           2,800,000 13,900,000 5,600,000 22,700,000    
Products                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           $ 35,663,000 $ 29,356,000 $ 69,608,000 $ 60,430,000    
Regulatory Milestones | EirGen Pharma Limited                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Maximum milestone payments   17,000,000                  
Sales Milestones | EirGen Pharma Limited                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Maximum milestone payments   $ 210,000,000                  
Exclusive Option | VFMCRP                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Maximum milestone payments       $ 555,000,000